Mineralys Therapeutics to Join Wells Fargo Healthcare Conference

RADNOR, Pa., Aug. 28, 2024 – Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company, has announced its participation in the Wells Fargo Healthcare Conference. The event is scheduled to take place in Boston, MA, from September 4 to 6, 2024.

The company's management is set to engage in a fireside chat on Thursday, September 5, 2024, at 1:30 PM EDT. This event will be available via a live webcast, which can be accessed in the "News and Events" section on the Investor Relations page of the Mineralys Therapeutics website. The webcast will be archived on the company’s website for a period of approximately 90 days following the event.

Mineralys Therapeutics is a biopharmaceutical company in the clinical stage, dedicated to developing treatments for hypertension, chronic kidney disease (CKD), and other conditions influenced by dysregulated aldosterone levels. The company's leading product candidate, lorundrostat, is an oral medication that selectively inhibits aldosterone synthase. This drug is currently under development for treating cardiorenal conditions, such as hypertension and CKD, which are impacted by abnormal aldosterone regulation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!